Tag: oral

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026

BOSTON, June 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target...

ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company ALK will present data and key insights within anaphylaxis, food and respiratory allergy.

2026 ASCO LBA | Juncell Therapeutics’ GC101 TIL Therapy Achieves Primary Endpoint in the Pivotal Phase II Trial for PD-1 Antibody Failed Advanced Melanoma

SHANGHAI, June 3, 2026 /PRNewswire/ -- On June 1 (Chicago time), in a Late-Breaking Abstract (LBA) oral presentation at the 2026 American Society of Clinical...

Transcontinental Inc. Announces Results for the Second Quarter of Fiscal Year 2026

Résultats pour le deuxième trimestre 2026

Globaltech Corp. (OTCQB: GLTK) Update to Shareholders

RENO, Nevada, June 03, 2026 (GLOBE NEWSWIRE) -- Globaltech Corporation (“Globaltech” or the “Company”) (OTCQB: GLTK), a U.S.-based technology holding company, is providing this Update to Shareholders to discuss: (i) how we are managing and operating the Company day to day, (ii) our near-term priorities with a long-term orientation, and (iii) how we responsibly and methodically approach innovation, including AI-enabled products and services.

Persist AI Teams up with Microsize and Micromacinazione (Micmac) to Launch First-of-Its-Kind Early-Stage “Micromill” Formulation Platform, Enabling Drug Development Decision With Milligrams of API

New collaboration delivers a fully integrated formulation workflow from early solubility studies to high-throughput dissolution, stability, and in-process analytics, making drug formulation less artisanal...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

Levicept to Present Data Suggesting LEVI-04 May Modify Disease in Osteoarthritis at EULAR 2026

Further clinical efficacy and pharmacology data also to be presented

Further clinical efficacy and pharmacology data also to be presented

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

Novo Nordisk is launching Wegovy® pill in the UAE, the first country outside the US, to make the Wegovy® pill available to people living with obesity

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN® Peanut chez les nourrissons âgés...

Châtillon, France, le 02 juin (22 :30 CEST) 2026

Four Michigan students advance to national finals of the Mott Million Dollar Challenge in Flint

Long Beach Community Care Campus Expansion Advances with $10 Million Investment from Centene Foundation and Health Net

Oh!mino Releases New Industry Report on Athletes Replacing Supplement Stacks with All-in-One EAA Formulas

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026

ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026

2026 ASCO LBA | Juncell Therapeutics’ GC101 TIL Therapy Achieves Primary Endpoint in the Pivotal Phase II Trial for PD-1 Antibody Failed Advanced Melanoma

Transcontinental Inc. Announces Results for the Second Quarter of Fiscal Year 2026

Globaltech Corp. (OTCQB: GLTK) Update to Shareholders

Persist AI Teams up with Microsize and Micromacinazione (Micmac) to Launch First-of-Its-Kind Early-Stage “Micromill” Formulation Platform, Enabling Drug Development Decision With Milligrams of API

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial...

Levicept to Present Data Suggesting LEVI-04 May Modify Disease in Osteoarthritis at EULAR 2026

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare’s Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026

DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN® Peanut chez les nourrissons âgés...

Explore

Press Releases

News & Opinion

Living

Others

Follow us